Recently the Cleveland Clinic’s Abby Statler discussed eligibility criteria exclusions for MDS clinical trials. She reports that observed outcomes indicate that eligibility criteria for patients with MDS relevant to liver function, renal function, and comorbidities should be relaxed. This could be especially the case for those with minor renal function abnormalities who evidenced comparable clinical outcomes to those without exhibiting similar abnormalities.
What is Myelodysplastic Syndrome (MDS)
MDS is a group of cancers in which immature blood cells in the bone marrow do not mature and therefore fail to become healthy blood cells. Early on, there are few symptoms, but later on, symptoms include fatigue, shortness of breath, easy bleeding, or frequent infections. Some types may develop into acute myeloid leukemia. About 7 out of 100,000 people are affected by the disease; about 4 out of 100,000 acquire the condition annually.
Rigid Trial Exclusion Criteria Needs to Change for MDS
American Journal of Managed Care (AJMC) interviewed Ms. Statler and asked why patients with therapy-related MDS are most often excluded from clinical trials involving MDS. Statler noted ...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).